MHRA limits retigabine indications

The MHRA has limited the use of the adjunctive anti-epileptic treatment retigabine (Trobalt) to patients with partial onset seizures with or without secondary generalisation where other appropriate drug combinations have proved inadequate or have not been tolerated.

The ophthalmic examination required when prescribing retigabine (Trobalt) should include a visual acuity test, dilated fundoscopy and a slit -lamp examination (pictured) | SCIENCE PHOTO LIBRARY
The ophthalmic examination required when prescribing retigabine (Trobalt) should include a visual acuity test, dilated fundoscopy and a slit -lamp examination (pictured) | SCIENCE PHOTO LIBRARY

The decision to restrict retigabine (Trobalt) was based on reports of adverse effects in long-term studies, including pigmentation of the skin, nails, lips and ocular tissues (including the retina).

Warn patient and perform eye examination before starting

When initiating therapy, healthcare professionals should inform patients of the risk of pigmentation with long-term treatment and perform a comprehensive ophthalmological examination before starting treatment and at least every 6 months thereafter.

Patients currently receiving retigabine should be identified and reviewed at a routine appointment. In addition, they should have an appointment scheduled for an ophthalmic examination.

MHRA Drug Safety Update July 2013

View Trobalt drug record

Further information: GlaxoSmithKline

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Fycompa: novel anticonvulsant for partial-onset seizures

Fycompa: novel anticonvulsant for partial-onset seizures

Fycompa (perampanel) is a new option for adjunctive...

Zonegran licensed as monotherapy in epilepsy

Zonegran licensed as monotherapy in epilepsy

Zonegran (zonisamide) has been approved for use as...

Lyrica (pregabalin) oral solution launched

Lyrica (pregabalin) oral solution launched

An oral liquid formulation of Lyrica (pregabalin) is...

Liquid formulation of Vimpat relaunched

Liquid formulation of Vimpat relaunched

The antiepileptic Vimpat (lacosamide) has been relaunched...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more